Equine & Livestock Product & Promotions Guide

2019 ZOETIS SPRING PROGRAM VETERINARIANS AND DEALERS 2019 SPRING PROGRAM REBATE LEVELS FEBRUARY 1 - APRIL 30, 2019 CATTLE PURCHASE CATEGORY (Includes Cattle Vaccines, Parasiticides, Select Reproductive Products and Synovex ® ) EQUINE PURCHASE CATEGORY (Includes Equine Vaccines* and Parasiticides) Purchase Threshold 2/1/19 - 3/14/19 Rebate Amount 3/15/19 - 4/30/19 Rebate Amount Purchase Threshold 2/1/19 - 3/14/19 Rebate Amount 3/15/19 - 4/30/19 Rebate Amount $5,000 2% 3% $1,000 2% 3% $30,000 4% 5% $7,500 4% 5% $60,000 5% 6% $12,500 5% 6% PURCHASE CATEGORY EARLY PURCHASE BONUS REBATE FEBRUARY 1-28, 2019 CATTLE – Select Reproductive Products, SYNOVEX 2% CATTLE – Vaccines 3% CATTLE – Parasiticides (DECTOMAX,® VALBAZEN®) 5% EQUINE – Vaccines,* Parasiticides 4% Terms • CATTLE: Cumulative purchases of DECTOMAX,® VALBAZEN,® cattle vaccines, FACTREL® Injection (gonadorelin injection), LUTALYSE® HighCon Injection (dinoprost tromethamine injection), LUTALYSE® Injection (dinoprost tromethamine injection), SYNOVEX® and SYNOVEX® ONE purchased during the offer will count toward the Cattle purchase threshold and will be eligible for the Cattle rebate. • EQUINE: Cumulative purchases of equine vaccines,* ANTHELCIDE® EQ Paste, QUEST® Gel/QUEST® PLUS Gel, SOLITUDE® IGR and STRONGID® purchased during the offer will count toward the Equine purchase threshold and be eligible for the Equine rebate. • EAZI-BREED™ CIDR® Cattle Insert count toward volume only for February and April, but are not rebate eligible. – EAZI-BREED™ CIDR® Cattle Insert will count toward volume AND be rebate eligible for the month of March only. Purchases must be billed and shipped from March 1, 2019 through March 31, 2019. • Customers can purchase in both Cattle and Equine product categories, but purchase thresholds will still be determined based on the product categories. The Cattle category requires a $5,000 minimum in cumulative purchase(s) to participate, and the Equine category requires a $1,000 minimum in cumulative purchase(s) to participate. • Eligible customers purchasing a minimum of $5,000 on a single, direct order of Dectomax, Valbazen, Lutalyse High Con, Lutalyse, Factrel, Cattle Eazi Breed CIDR, Cattle Vaccine, Synovex, Synovex ONE, Equine Parasiticides and Equine Vaccine directly from Zoetis will receive standard plus 60 days (90 days total) on eligible products billed and shipped February 1, 2019, through April 30, 2019. If you purchase from a distributor, please contact that distributor regarding terms. • Eligible customers will receive an additional 1% rebate on qualifying purchases from March 15, 2019 through April 30, 2019 as detailed in the table above. • All puchases must invoice between March 15, 2019 through April 30, 2019 to qualify for the additional 1% rebate. • Advertised pricing should not be below reseller suggested pricing. If advertised pricing is below these suggested levels, Zoetis reserves the right to withhold any earned program rebates. • Eligible accounts must qualify for each purchase level threshold at the billing account level to receive rebate. Back orders are not eligible. Rebates will be paid via single check to the parent NARC. Child locations are not eligible to receive the rebate. The qualification rebate including early purchase bonus will be paid by June 23, 2019. Zoetis reserves the right to modify or discontinue this program at any time and for any reason. For more information, talk to your local Zoetis representative. All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. CIDR is a registered trademark of InterAg. © 2019 Zoetis Services LLC. All rights reserved. GCA-00310 *Rebates on ARVAC,® PINNACLE® I.N., EQUINE ROTAVIRUS VACCINE** and and CORE EQ INNOVATOR™ will be paid on purchases by Veterinarians with valid veterinary-client-patient relationships (VCPR) who are buying these products for patients under their care. For Dealers, these vaccines are NOT eligible for threshold or rebate. **This product is conditionally licensed while additional efficacy and potency data are being developed.

• Cover